Human epidermal growth factor receptor-2 (HER2) is a potential therapeutic target in extramammary Paget's disease of the vulva.

Michele BartolettiRoberta MazzeoMarco De ScordilliAnna Del FabroMaria Grazia VitaleLucia BortotMilena Sabrina NicolosoSerena CorsettiMarta BonottoSimona ScaloneGiorgio GiordaRoberto SorioClaudia AndreettaMaria Luisa MeacciRocco De VivoGianpiero FasolaFrancesco SopracordevoleFabio Puglisi

Published in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2020)

Advanced vulvar Paget's disease is a rare disorder and no standard treatment is available. In the sub-group of HER2 positive disease, weekly paclitaxel-trastuzumab appears to be active and safe, and may be considered a therapeutic option in these patients.

Keyphrases

epidermal growth factor receptor
tyrosine kinase
end stage renal disease
endothelial cells
advanced non small cell lung cancer
chronic kidney disease
newly diagnosed
ejection fraction
prognostic factors
early stage
radiation therapy
patient reported outcomes
neoadjuvant chemotherapy
metastatic breast cancer